Court Found No Wrongdoing by Lynn Stockwell; Judgment Imposed Joint and Several Liability Due to Counsel’s Failure Cibola County, New Mexico, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC: BGXXQ) and its Chief Executive Officer, Lynn Stockwell, today announced the filing of a landmark lawsuit seeking damages in excess of $3 billion against Rodey Law Firm and Attorneys’ Liability Assurance Society (ALAS). The complaint, filed in the Thirteenth Judicial District Court of New Mexico, alleges ...

Group 1 - The core viewpoint of the news highlights the recent merger between Bright Green Corporation and PharmAGRI Capital Partners, emphasizing the strategic move to bring manufacturing back to the U.S. by executing a Letter of Intent with Tesla for the procurement of 10,000 robots [1] - The robotics sector is experiencing a surge, driven by the aforementioned merger and procurement deal, leading to a notable increase in the automotive parts ETF, which rose over 1.0% and achieved a four-day winning streak [1] - The China Securities Automotive Parts Theme Index, which includes 100 listed companies involved in various automotive components, reflects the overall performance of the automotive parts sector [1] Group 2 - As of August 29, 2025, the top ten weighted stocks in the China Securities Automotive Parts Theme Index (931230) include companies such as Huichuan Technology, Fuyao Glass, and Sanhua Intelligent Control, collectively accounting for 41.54% of the index [2] - The automotive parts ETF (159306) has several off-market connections, including Ping An China Securities Automotive Parts Theme ETF Connect A, C, and E [2]

Core Insights - Bright Green Corporation (OTC: BGXX) has merged with PharmAGRI Capital Partners to enhance U.S. drug manufacturing sovereignty through a court-supervised restructuring plan [1] - Lynn Stockwell has been appointed as the CEO and Chairwoman of PharmAGRI, with plans to form a new board from her acquisition corps focused on DEA-licensed and FDA-compliant pharmaceutical businesses [2] - PharmAGRI's model emphasizes a "seed to syringe" approach for drug manufacturing entirely within the U.S., supporting EB-5 investor pathways and federal contracts [3] Company Strategy - PharmAGRI has signed a Letter of Intent with Tesla to deploy up to 10,000 Optimus 3+ humanoid robots for various operations, aimed at improving labor compliance and reducing reliance on low-wage labor [4] - The strategic vision includes on-shoring pharmaceutical production, enhancing wages, and establishing a sovereign infrastructure capable of securing federal contracts [5] - PharmAGRI plans to file a Form S-1 registration statement with the SEC and aims for a Nasdaq relisting, with a proposed reverse stock split and preferred share issuance pending approval [5][6] Market Positioning - The company intends to complete its IPO by the end of 2025, which will facilitate market access and strategic expansion in the U.S. pharmaceutical sector [6] - The merger and partnership with Tesla are expected to strengthen PharmAGRI's mergers and acquisitions strategy, aiming to grow revenue and consolidate production assets [6]

Core Insights - Bright Green Corporation (OTC: BGXX) has merged with PharmAGRI Capital Partners to enhance U.S. drug manufacturing sovereignty through a court-supervised restructuring plan [1] - Lynn Stockwell has been appointed as the CEO and Chairwoman of PharmAGRI, with plans to form a new board from her acquisition corps focused on DEA-licensed and FDA-compliant pharmaceutical businesses [2] - PharmAGRI's model emphasizes a "seed to syringe" approach for drug manufacturing entirely in the U.S., supporting EB-5 investor pathways and federal contracts [3] Company Strategy - PharmAGRI has signed a Letter of Intent with Tesla to deploy up to 10,000 Optimus 3+ humanoid robots for various operations, aimed at improving labor compliance and reducing reliance on low-wage labor [4] - The strategic vision includes on-shoring pharmaceutical production, enhancing wages, and establishing a sovereign infrastructure to secure federal contracts and strengthen the U.S. supply chain [5] - PharmAGRI plans to file a Form S-1 registration statement with the SEC and aims for a Nasdaq relisting, with a proposed reverse stock split and preferred share issuance pending approval [5][6] Market Positioning - The company intends to complete its IPO by the end of 2025, which will facilitate market access and strategic expansion within the U.S. pharmaceutical infrastructure [6]

Core Insights - Bright Green Corporation is seeking court approval for a Restructuring Security Agreement to provide new equity for the company, ensuring full payment to creditors while allowing existing equity shareholders to retain their interests without dilution [1] Group 1: Company Strategy and Leadership - Lynn Stockwell, the new CEO and Chairman, is managing other NASDAQ listed corporations and plans to raise over $2 billion for acquisitions in the pharmaceutical sector [2] - The company aims to establish a reliable U.S. domiciled supply chain for plant-based legal controlled substances, focusing on end-to-end prescription drug manufacturing and home delivery [3] Group 2: Market Opportunity - The total addressable market for drugs purchased in the U.S. exceeds $100 billion, presenting a significant opportunity for Bright Green [4] - The company plans to invest $3.5 billion in building DEA and FDA compliant facilities, which will create thousands of jobs in rural areas [5] Group 3: Revenue Generation - Planned revenue streams include supply contracts for controlled substances and the EB-5 investment program, which could generate significant capital from foreign applicants seeking U.S. residency [6]